Targeting XBP1 as a pivotal effector of the UPR in combination with the dual inhibitor of PI3K/mTOR, BEZ235, could therefore represent a promising potential therapeutic approach for the treatment of oncogenic RAS in NRASG12D pre‐B ALL. Here, MTOR is linked to acute lymphoblastic leukemia.